Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy

Oliveira Hauer, Kevin LU ; Pawlik, Daria LU orcid ; Leuzy, Antoine LU ; Janelidze, Shorena LU ; Hall, Sara LU ; Hansson, Oskar LU orcid and Smith, Ruben LU (2023) In Parkinsonism and Related Disorders 106.
Abstract

Introduction: The diagnosis of progressive supranuclear palsy (PSP) is often challenging since PSP may clinically resemble other neurodegenerative disorders. Recently, the tau PET tracer [18F]RO948, a potential new biomarker for PSP, was developed. The aim of this study was to determine the ability of three different biomarkers, including [18F]RO948 PET, to distinguish PSP patients from healthy controls and from patients with α-synucleinopathies. Methods: Patients with PSP (n = 23), α-synucleinopathies (n = 47) and healthy controls (n = 61) were included from the BioFINDER-2 study. [18F]RO948 standardized uptake value ratios (SUVR), magnetic resonance imaging midbrain/pons ratio, and cerebrospinal fluid... (More)

Introduction: The diagnosis of progressive supranuclear palsy (PSP) is often challenging since PSP may clinically resemble other neurodegenerative disorders. Recently, the tau PET tracer [18F]RO948, a potential new biomarker for PSP, was developed. The aim of this study was to determine the ability of three different biomarkers, including [18F]RO948 PET, to distinguish PSP patients from healthy controls and from patients with α-synucleinopathies. Methods: Patients with PSP (n = 23), α-synucleinopathies (n = 47) and healthy controls (n = 61) were included from the BioFINDER-2 study. [18F]RO948 standardized uptake value ratios (SUVR), magnetic resonance imaging midbrain/pons ratio, and cerebrospinal fluid neurofilament light (NfL) levels were compared between diagnostic groups individually and in combination. Results: [18F]RO948 PET SUVR in the globus pallidus, NfL, and midbrain/pons area ratios were all able to differentiate PSP patients from controls and from patients with α-synucleinopathies ([18F]RO948 [mean ± SD]: controls 1.24 ± 0.22; PSP 1.47 ± 0.4; PD 1.18 ± 0.2; DLB 1.25 ± 0.24, p < 0.05), (NfL pg/mL [mean ± SD]: controls 1055 ± 569; PSP 2197 ± 1010; PD 1038 ± 416; DLB 1548 ± 687, p < 0.001) and (midbrain/pons ratio [mean ± SD]: controls 0.46 ± 0.07; PSP 0.34 ± 0.09; PD 0.43 ± 0.06; DLB 0.40 ± 0.07, p < 0.01). Receiver operating characteristic (ROC) analyses indicated that combining the three biomarkers resulted in the highest area under the ROC values (0.94 [0.88–1.00]) for separating controls from PSP and (0.92 [0.85–0.99]) for separating PSP from α-synucleinopathies. Conclusions: All studied biomarkers could individually separate PSP from controls and α-synucleinopathies patients at a group level. The optimal prediction models included NfL and midbrain/pons ratio for separating controls from PSP and all three biomarkers for separating PSP from α-synucleinopathies.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Parkinsonism and Related Disorders
volume
106
article number
105226
publisher
Elsevier
external identifiers
  • scopus:85142699408
  • pmid:36442367
ISSN
1353-8020
DOI
10.1016/j.parkreldis.2022.11.018
language
English
LU publication?
yes
id
ee24174a-e336-466e-84c5-1b077f2d5faa
date added to LUP
2023-01-31 15:05:55
date last changed
2024-06-11 01:41:09
@article{ee24174a-e336-466e-84c5-1b077f2d5faa,
  abstract     = {{<p>Introduction: The diagnosis of progressive supranuclear palsy (PSP) is often challenging since PSP may clinically resemble other neurodegenerative disorders. Recently, the tau PET tracer [<sup>18</sup>F]RO948, a potential new biomarker for PSP, was developed. The aim of this study was to determine the ability of three different biomarkers, including [<sup>18</sup>F]RO948 PET, to distinguish PSP patients from healthy controls and from patients with α-synucleinopathies. Methods: Patients with PSP (n = 23), α-synucleinopathies (n = 47) and healthy controls (n = 61) were included from the BioFINDER-2 study. [<sup>18</sup>F]RO948 standardized uptake value ratios (SUVR), magnetic resonance imaging midbrain/pons ratio, and cerebrospinal fluid neurofilament light (NfL) levels were compared between diagnostic groups individually and in combination. Results: [<sup>18</sup>F]RO948 PET SUVR in the globus pallidus, NfL, and midbrain/pons area ratios were all able to differentiate PSP patients from controls and from patients with α-synucleinopathies ([<sup>18</sup>F]RO948 [mean ± SD]: controls 1.24 ± 0.22; PSP 1.47 ± 0.4; PD 1.18 ± 0.2; DLB 1.25 ± 0.24, p &lt; 0.05), (NfL pg/mL [mean ± SD]: controls 1055 ± 569; PSP 2197 ± 1010; PD 1038 ± 416; DLB 1548 ± 687, p &lt; 0.001) and (midbrain/pons ratio [mean ± SD]: controls 0.46 ± 0.07; PSP 0.34 ± 0.09; PD 0.43 ± 0.06; DLB 0.40 ± 0.07, p &lt; 0.01). Receiver operating characteristic (ROC) analyses indicated that combining the three biomarkers resulted in the highest area under the ROC values (0.94 [0.88–1.00]) for separating controls from PSP and (0.92 [0.85–0.99]) for separating PSP from α-synucleinopathies. Conclusions: All studied biomarkers could individually separate PSP from controls and α-synucleinopathies patients at a group level. The optimal prediction models included NfL and midbrain/pons ratio for separating controls from PSP and all three biomarkers for separating PSP from α-synucleinopathies.</p>}},
  author       = {{Oliveira Hauer, Kevin and Pawlik, Daria and Leuzy, Antoine and Janelidze, Shorena and Hall, Sara and Hansson, Oskar and Smith, Ruben}},
  issn         = {{1353-8020}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Parkinsonism and Related Disorders}},
  title        = {{Performance of [<sup>18</sup>F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy}},
  url          = {{http://dx.doi.org/10.1016/j.parkreldis.2022.11.018}},
  doi          = {{10.1016/j.parkreldis.2022.11.018}},
  volume       = {{106}},
  year         = {{2023}},
}